A practical reference on investigational status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-17. Anything still debated is marked as such rather than presented as settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
=== Membrane protein databases === TCDB - Transporter Classification database, a comprehensive classification of transmembrane transporter proteins Orientations of Proteins in Membranes (OPM) database - 3D structures of integral and peripheral membrane proteins arranged in the lipid bilayer Protein Data Bank of Transmembrane Proteins - 3D models of transmembrane proteins approximately arranged in the lipid bilayer. TransportDB - Genomics-oriented database of transporters from TIGR Membrane PDB Archived 2020-08-03 at the Wayback Machine - Database of 3D structures of integral membrane proteins and hydrophobic peptides with an emphasis on crystallization conditions Mpstruc database Archived 2013-12-25 at the Wayback Machine - A curated list of selected transmembrane proteins from the Protein Data Bank MemProtMD - a database of membrane protein structures simulated by coarse-grained molecular dynamics Membranome database provides information about bitopic proteins from several model organisms
These two are the heaviest isotopes of dubnium to date, and both were produced as a result of decay of the heavier nuclei 288Mc and 294Ts rather than directly, because the experiments that yielded them were originally designed in Dubna for 48Ca beams. For its mass, 48Ca has by far the greatest neutron excess of all practically stable nuclei, both quantitative and relative, which correspondingly helps synthesize superheavy nuclei with more neutrons, but this gain is compensated by the decreased likelihood of fusion for high atomic numbers.
on radiation protection in medical X-ray equipment on radiation protection in shoe X-ray machines (of which about 850 were in operation in 1963; the last one was not decommissioned until 1990) on the radioactivity of luminous dials. Another 40 regulations followed. The monitoring of such facilities took many years due to a lack of personnel. From 1963, dosimeters were to be used for personal protection, but this met with great resistance. It was not until 1989 that an updated radiation protection law was passed, accompanied by radiation protection training for the people concerned.
The field of organic molecular cages emerged in the early 2000s, pioneered by the work of Cram, Lehn, and Pedersen, whose foundational research on host-guest chemistry and molecular recognition earned them the 1987 Nobel Prize. The area, which relies on molecular self-assembly, is inspired by biological precedents are ferritin, capsid, and the tobacco mosaic virus, which are formed by the self-assembly of protein subunits into a polyhedral symmetry. Large organic cages were reported by Tozawa and Cooper in 2009, introducing permanently porous organic cages with intrinsic cavities. The ability to control cavity size and chemical environment at the molecular level distinguishes these materials from traditional porous systems.
Sources: en.wikipedia.org
=== October === 8 October – Tánaiste Micheál Martin said that the Department of Foreign Affairs had been in touch with the family of Kim Damti (22), an Irish-Israeli woman who was unaccounted for following the previous day's series of attacks launched by Hamas on Israel. On 11 October, Damti was confirmed dead. 10 October – Minister for Finance Michael McGrath and Minister for Public Expenditure, National Development Plan Delivery and Reform Paschal Donohoe announced Budget 2024, with three electricity credits for all households, a €12 increase to core social welfare payments and half-price travel for those aged under 25. 23 October – Yousef Palani was sentenced to two life sentences plus 20 years for the murder of two men and the stabbing of a third in Sligo, all of who he had sought out on a pretence of dating. 25 October – The Health Products Regulatory Authority (HPRA) said it had seized 254 units of falsified Semaglutide, a drug used for type 2 diabetes and as an unofficial aide to weight loss, during 2023. 27 October – Latest figures showed that homelessness in Ireland hit new records: 8,923 adults and 3,904 children accessed emergency accommodation in September 2023, bringing the total to 12,827 people.
In turn, both actions reduce the C term caused by a slow mass transfer from the stationary phase to the mobile phase. Further optimization of efficiency can be gained by reducing the flow rate to one closely matched to that derived from the Knox equation. Overall, the three proposed theories seemed to have contributing effects of the poor efficiency observed, and can be partially countered by the addition of organic modifiers, particularly alcohol, and increasing the column temperature.
A subset of progeria patients with heterozygous mutations of LMNA have presented an atypical form of the condition, with initial symptoms not developing until late childhood or early adolescence. These patients have had longer lifespans than those with typical-onset progeria. This atypical form is extremely rare, with presentations of the condition varying between patients with even the same mutation. The general phenotype of atypical cases is consistent with typical progeria, but other factors (severity, onset, and lifespan) vary in presentation.
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 3,4-DMA's dose as "a few hundred milligrams" (route unspecified) and its duration as unknown. A dose of approximately 70 mg intravenously produced insignificant to slight psychoactive effects in two individuals. Conversely, a subsequent approximate 700 mg dose intravenously in the same two people produced a definite mescaline-like state, including visual hallucinations (e.g., geometric figures and occasional structured forms), visual distortions, after-images, feelings of unreality, paranoia, marked pupil dilation, and gross body tremors. Gordon Alles reported 3,4-DMA to be inactive at doses of 10 to 120 mg orally but active at 160 mg orally, with reported effects including increased blood pressure, slight pupil dilation, lacrimation, and gastrointestinal uneasiness. He estimated that the response at this dose was equivalent to that of about 60 to 80 mg 3,4-methylenedioxyamphetamine (MDA), suggesting that 3,4-DMA's potency may be about 2- to 3-fold lower than that of MDA and may fall midway between that of MDA and mescaline. Alternatively, according to Shulgin, 3,4-DMA may have comparable potency to mescaline, with an effective dose of perhaps 300 to 400 mg orally, or may be less potent than mescaline. Richard Glennon suggested that the dose may be 400 to 700 mg orally.
More color variants are possible via chromophore binding. The critical mutation in cyan derivatives is the Y66W substitution, which causes the chromophore to form with an indole rather than phenol component. Several additional compensatory mutations in the surrounding barrel are required to restore brightness to this modified chromophore due to the increased bulk of the indole group. In ECFP and Cerulean, the N-terminal half of the seventh strand exhibits two conformations. These conformations both have a complex set of van der Waals interactions with the chromophore. The Y145A and H148D mutations in Cerulean stabilize these interactions and allow the chromophore to be more planar, better packed, and less prone to collisional quenching. Additional site-directed random mutagenesis in combination with fluorescence lifetime based screening has further stabilized the seventh β-strand resulting in a bright variant, mTurquoise2, with a quantum yield (QY) of 0.93. The red-shifted wavelength of the YFP derivatives is accomplished by the T203Y mutation and is due to π-electron stacking interactions between the substituted tyrosine residue and the chromophore. These two classes of spectral variants are often employed for Förster resonance energy transfer (FRET) experiments. Genetically encoded FRET reporters sensitive to cell signaling molecules, such as calcium or glutamate, protein phosphorylation state, protein complementation, receptor dimerization, and other processes provide highly specific optical readouts of cell activity in real time.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.